Countdown to TransMedics (TMDX) Q2 Earnings: Wall Street Forecasts for Key Metrics

Core Insights - Wall Street analysts forecast TransMedics (TMDX) will report quarterly earnings of $0.48 per share, reflecting a year-over-year increase of 37.1% [1] - Anticipated revenues for the quarter are projected to be $147.37 million, representing a 28.9% increase compared to the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the past 30 days, indicating analysts' reassessment of their projections [1] Revenue Estimates - Analysts predict 'Net revenue by OCS product- OCS Lung net revenue' will reach $4.50 million, indicating a year-over-year decrease of 4.2% [4] - The estimate for 'Net revenue by OCS product- OCS Liver net revenue' is $108.56 million, showing a significant increase of 40.9% from the prior-year quarter [4] - 'Net revenue by OCS product- OCS Heart net revenue' is expected to be $32.38 million, reflecting a 3% increase from the previous year [4] Geographic Revenue Insights - 'Geographic Revenues- United States' is expected to be $142.05 million, indicating a year-over-year increase of 31% [5] - 'Geographic Revenues- All other countries' is projected to be $4.47 million, showing a decrease of 5.2% from the prior-year quarter [5] Stock Performance - TransMedics shares have decreased by 17.8% over the past month, contrasting with the Zacks S&P 500 composite's increase of 4.9% [5] - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [5]